Navigation Links
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis

age in Germany has actinic keratosis, the incidence doubles every 10 years. We will develop the 10 % formulation further for the treatment of this unusually frequent disease and intend to bring it to registration by 2009," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG.

About Biofrontera AG Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close to the market product portfolio and a solid liquidity. Biofrontera is listed in the regulated market of the Düsseldorf stock exchange under the symbol B8F and the ISIN number DE0006046113. http://www.biofrontera.com/

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

For further information please contact:

Anke zur Mühlen Corporate Communication

+ 49 (0) 214 87632 22 + 49 (0) 214 87632 90 a.zurmuehlen@biofrontera.com

Biofrontera AG Hemmelrather Weg 201 D- 51377 Leverkusen, Germany


'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... Perrigo Company (Nasdaq: PRGO ; ... Cooperation and License agreements with Brilite Nutritionals (Shanghai) ... company. Under these agreements, Perrigo will supply its ... will exclusively source all its infant formula requirements ...
... and HERZLIYA PITUACH, Israel, Nov. 8, 2011 ... -- SMT Research & Development, Ltd. ("SMT") ... as Vice President and General Manager.  Mr. Porath will ... company,s development and production facility in Herzliya Pituach, Israel, ...
Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Brilite Nutritionals (Shanghai) Co., Ltd. 2SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence 2SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence 3
(Date:8/30/2015)... , ... August 31, 2015 , ... ... and a third of tax receipts, issues that are critically important to them ... bands of attorneys and lobbyists monitoring proposed legislation and changing tax and regulatory ...
(Date:8/30/2015)... (PRWEB) , ... August 31, 2015 , ... ... Magazine: The Fun Cooking Magazine for Kids , recently elected two new officers ... These appointments will further ChopChop’s mission of inspiring and teaching kids to cook ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... today announced it is a Silver Sponsor of the Digital Workplace Conference, taking ... Centre in Auckland, NZ. Throughout the event, AvePoint will showcase its file analysis, ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... that Brian Spector has joined the company as the new Global Communications Director ... broadcasting and public relations experience having spent the last 16 years doing on-air ...
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 ... ... that Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical ... cosmeceutical and skin care experience having spent the last 25 years working in ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
... As ... be welcoming world leaders to the David L. Lawrence Convention Center, the largest "green" ... Design) certification. , ... Pittsburgh, Pa. (PRWEB) September 24, 2009 -- As the industry leader in automatic door ...
... , , , SEATTLE, ... launched the Living Proof Project: U.S. Investments in Global Health ... success of the U.S. government,s efforts to improve health around ... Project will show that U.S.-supported initiatives to fight malaria, AIDS, ...
... , , , INDIANAPOLIS, ... District of Indiana today upheld Eli Lilly and Company,s (NYSE: ... tablets). In the case of Eli Lilly and Company ... favor of Lilly on all accounts for these method-of-use patents, ...
... , , , ... Northern Ireland, moderated by President Clinton, featured Peter Robinson, first ... Northern Ireland Executive; Declan Kelly, economic envoy to Northern Ireland, ... Northern Ireland; and Micheal Martin, Minster of Foreign ...
... Sept. 23 Allowing age adjustments more restrictive than 5 to ... in the individual insurance market, making coverage unaffordable for many according ... Cross and Blue Shield Association (BCBSA) released today new data, prepared ... that a 2 to 1 age rating ratio would increase premiums ...
... NEW YORK, Sept. 23 The Michael J. ... to successfully translate neurotrophic factor advances from pre-clinical and early-phase ... The funding will be awarded under a new Directed ... , , The Foundation,s intention is to ...
Cached Medicine News:Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 2Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 3Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 2Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 2Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 4Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 5Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 6Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 7Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 8Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 9Health News:Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage 2Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: